A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis

Adil Eddie Bharucha, Roberta Jorgensen, S. N. Lichtman, Nicholas F La Russo, K. D. Lindor

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

OBJECTIVE: There is no effective therapy for patients with primary sclerosing cholangitis (PSC). Rats with experimental small bowel bacterial overgrowth develop hepatobiliary injury similar to PSC. The hepatobiliary injury results from peptidoglycan-polysaccharide-mediated activation of Kupffer cells, release of cytokines such as tumor necrosis factor (TNF-α), and is prevented by pentoxifylline. Our aims were to assess the safety and effects of pentoxifylline on symptoms and biochemical liver tests in patients with PSC. METHODS: A total of 20 patients with clinical, cholangiographic, and histological features of PSC of varying severity were treated with pentoxifylline sustained release (SR) tablets (400 mg q.i.d.) for ≤1 yr. Serum alkaline phosphatase, aspartate aminotransferase, and bilirubin were monitored every 3 months for 1 year; serum TNF-α and TNF receptor subtypes I and II were assessed at baseline and 1 year. RESULTS: Of 20 patients, 16 tolerated pentoxifylline and completed the study. Two patients were withdrawn because of severe nausea, and two patients were noncompliant with medication and withdrew. Pentoxifylline did not significantly alter symptoms of fatigue or pruritus, serum liver tests, serum TNF-α or TNF receptor levels. CONCLUSIONS: In the current regimen, pentoxifylline alone does not significantly improve symptoms or liver tests in patients with PSC. (C) 2000 by Am. Coll. of Gastroenterology.

Original languageEnglish (US)
Pages (from-to)2338-2342
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume95
Issue number9
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Pentoxifylline
Sclerosing Cholangitis
Tumor Necrosis Factor Receptors
Serum
Therapeutics
Liver
Kupffer Cells
Peptidoglycan
Wounds and Injuries
Gastroenterology
Pruritus
Aspartate Aminotransferases
Bilirubin
Nausea
Tablets
Fatigue
Polysaccharides
Alkaline Phosphatase
Tumor Necrosis Factor-alpha
Cytokines

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. / Bharucha, Adil Eddie; Jorgensen, Roberta; Lichtman, S. N.; La Russo, Nicholas F; Lindor, K. D.

In: American Journal of Gastroenterology, Vol. 95, No. 9, 2000, p. 2338-2342.

Research output: Contribution to journalArticle

@article{52b1d5539c384cb9874c3ef574055eb5,
title = "A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis",
abstract = "OBJECTIVE: There is no effective therapy for patients with primary sclerosing cholangitis (PSC). Rats with experimental small bowel bacterial overgrowth develop hepatobiliary injury similar to PSC. The hepatobiliary injury results from peptidoglycan-polysaccharide-mediated activation of Kupffer cells, release of cytokines such as tumor necrosis factor (TNF-α), and is prevented by pentoxifylline. Our aims were to assess the safety and effects of pentoxifylline on symptoms and biochemical liver tests in patients with PSC. METHODS: A total of 20 patients with clinical, cholangiographic, and histological features of PSC of varying severity were treated with pentoxifylline sustained release (SR) tablets (400 mg q.i.d.) for ≤1 yr. Serum alkaline phosphatase, aspartate aminotransferase, and bilirubin were monitored every 3 months for 1 year; serum TNF-α and TNF receptor subtypes I and II were assessed at baseline and 1 year. RESULTS: Of 20 patients, 16 tolerated pentoxifylline and completed the study. Two patients were withdrawn because of severe nausea, and two patients were noncompliant with medication and withdrew. Pentoxifylline did not significantly alter symptoms of fatigue or pruritus, serum liver tests, serum TNF-α or TNF receptor levels. CONCLUSIONS: In the current regimen, pentoxifylline alone does not significantly improve symptoms or liver tests in patients with PSC. (C) 2000 by Am. Coll. of Gastroenterology.",
author = "Bharucha, {Adil Eddie} and Roberta Jorgensen and Lichtman, {S. N.} and {La Russo}, {Nicholas F} and Lindor, {K. D.}",
year = "2000",
doi = "10.1016/S0002-9270(00)01116-3",
language = "English (US)",
volume = "95",
pages = "2338--2342",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis

AU - Bharucha, Adil Eddie

AU - Jorgensen, Roberta

AU - Lichtman, S. N.

AU - La Russo, Nicholas F

AU - Lindor, K. D.

PY - 2000

Y1 - 2000

N2 - OBJECTIVE: There is no effective therapy for patients with primary sclerosing cholangitis (PSC). Rats with experimental small bowel bacterial overgrowth develop hepatobiliary injury similar to PSC. The hepatobiliary injury results from peptidoglycan-polysaccharide-mediated activation of Kupffer cells, release of cytokines such as tumor necrosis factor (TNF-α), and is prevented by pentoxifylline. Our aims were to assess the safety and effects of pentoxifylline on symptoms and biochemical liver tests in patients with PSC. METHODS: A total of 20 patients with clinical, cholangiographic, and histological features of PSC of varying severity were treated with pentoxifylline sustained release (SR) tablets (400 mg q.i.d.) for ≤1 yr. Serum alkaline phosphatase, aspartate aminotransferase, and bilirubin were monitored every 3 months for 1 year; serum TNF-α and TNF receptor subtypes I and II were assessed at baseline and 1 year. RESULTS: Of 20 patients, 16 tolerated pentoxifylline and completed the study. Two patients were withdrawn because of severe nausea, and two patients were noncompliant with medication and withdrew. Pentoxifylline did not significantly alter symptoms of fatigue or pruritus, serum liver tests, serum TNF-α or TNF receptor levels. CONCLUSIONS: In the current regimen, pentoxifylline alone does not significantly improve symptoms or liver tests in patients with PSC. (C) 2000 by Am. Coll. of Gastroenterology.

AB - OBJECTIVE: There is no effective therapy for patients with primary sclerosing cholangitis (PSC). Rats with experimental small bowel bacterial overgrowth develop hepatobiliary injury similar to PSC. The hepatobiliary injury results from peptidoglycan-polysaccharide-mediated activation of Kupffer cells, release of cytokines such as tumor necrosis factor (TNF-α), and is prevented by pentoxifylline. Our aims were to assess the safety and effects of pentoxifylline on symptoms and biochemical liver tests in patients with PSC. METHODS: A total of 20 patients with clinical, cholangiographic, and histological features of PSC of varying severity were treated with pentoxifylline sustained release (SR) tablets (400 mg q.i.d.) for ≤1 yr. Serum alkaline phosphatase, aspartate aminotransferase, and bilirubin were monitored every 3 months for 1 year; serum TNF-α and TNF receptor subtypes I and II were assessed at baseline and 1 year. RESULTS: Of 20 patients, 16 tolerated pentoxifylline and completed the study. Two patients were withdrawn because of severe nausea, and two patients were noncompliant with medication and withdrew. Pentoxifylline did not significantly alter symptoms of fatigue or pruritus, serum liver tests, serum TNF-α or TNF receptor levels. CONCLUSIONS: In the current regimen, pentoxifylline alone does not significantly improve symptoms or liver tests in patients with PSC. (C) 2000 by Am. Coll. of Gastroenterology.

UR - http://www.scopus.com/inward/record.url?scp=0033829920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033829920&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(00)01116-3

DO - 10.1016/S0002-9270(00)01116-3

M3 - Article

C2 - 11007239

AN - SCOPUS:0033829920

VL - 95

SP - 2338

EP - 2342

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -